Detalles de la búsqueda
1.
High levels of health-related quality of life five years after curative treatment of prostate cancer with HDR-brachytherapy and external beam radiation.
Acta Oncol
; 61(10): 1179-1185, 2022 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-36062835
2.
High rate of local control and cure at 10 years after treatment of prostate cancer with external beam radiotherapy and high-dose-rate brachytherapy: a single centre experience.
Acta Oncol
; 60(10): 1301-1307, 2021 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-34498986
3.
Comorbidity as a predictor of overall survival in prostate cancer patients treated with external beam radiotherapy combined with HDR brachytherapy boosts.
Acta Oncol
; 56(1): 21-26, 2017 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-27882806
4.
Capture rate and representativity of The National Prostate Cancer Register of Sweden.
Acta Oncol
; 54(2): 158-63, 2015 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-25034349
5.
Time difference in retrieving clinical information in Patient-overview Prostate Cancer compared to electronic health records.
Scand J Urol
; 56(2): 95-101, 2022 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-35107408
6.
Health-related Quality of Life in Intermediate- or High-risk Patients Treated With Radical External Radiotherapy and Adjuvant Docetaxel for Localized Prostate Cancer: A Randomized, Phase III SPCG-13 Study.
Anticancer Res
; 42(1): 87-92, 2022 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-34969712
7.
Time spent in hormone-sensitive and castration-resistant disease states in men with advanced prostate cancer, and its health economic impact: registry-based study in Sweden.
Scand J Urol
; 55(1): 1-8, 2021 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-33300403
8.
Set-up and preliminary results from the Patient-overview Prostate Cancer. Longitudinal registration of treatment of advanced prostate cancer in the National Prostate Cancer Register of Sweden.
Scand J Urol
; 54(3): 227-234, 2020 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-32363988
9.
The ProBio trial: molecular biomarkers for advancing personalized treatment decision in patients with metastatic castration-resistant prostate cancer.
Trials
; 21(1): 579, 2020 Jun 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-32586393
10.
Docetaxel Versus Surveillance After Radical Radiotherapy for Intermediate- or High-risk Prostate Cancer-Results from the Prospective, Randomised, Open-label Phase III SPCG-13 Trial.
Eur Urol
; 76(6): 823-830, 2019 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-31443961
11.
Nationwide population-based study on the use of novel antiandrogens in men with prostate cancer in Sweden.
Scand J Urol
; 52(2): 143-150, 2018 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-29385878
12.
Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA.
J Clin Oncol
; 35(28): 3189-3197, 2017 Oct 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28753384
13.
Long-term health-related quality of life after curative treatment for prostate cancer: a regional cross-sectional comparison of two standard treatment modalities.
Int J Oncol
; 46(1): 381-8, 2015 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-25355465
14.
Corrigendum re "Docetaxel Versus Surveillance After Radical Radiotherapy for Intermediate- or High-risk Prostate Cancer-Results from the Prospective, Randomised, Open-label Phase III SPCG-13 Trial" [Eur Urol 2019;76:823-30].
Eur Urol
; 78(6): e241-e242, 2020 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-32893063
15.
Undertreatment of Men in Their Seventies with High-risk Nonmetastatic Prostate Cancer.
Eur Urol
; 68(1): 53-8, 2015 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-25813688
16.
The updated ESTRO core curricula 2011 for clinicians, medical physicists and RTTs in radiotherapy/radiation oncology.
Radiother Oncol
; 103(1): 103-8, 2012 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-22444243
Resultados
1 -
16
de 16
1
Próxima >
>>